Compare GameStop Corp. (GME) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GameStop Corp. vs Johnson & Johnson — how do they compare? GameStop Corp. trades at $26.55 (market cap $12.75B), while Johnson & Johnson trades at $256.5 (market cap $618.09B). The key difference: Johnson & Johnson is far larger — about 48.5× GameStop Corp.'s market cap, and Johnson & Johnson pays a 2.09% dividend while GameStop Corp. pays none. Which is the better fit depends on your goals — on Pluang, investors hold GameStop Corp. for 62 Days and Johnson & Johnson for 129 Days on average.
| GME | JNJ | |
|---|---|---|
Market Cap | $12.75B | $618.09B |
Volume | 13,026,993 | 6,050,983 |
Sector | Consumer Cyclical | Health |
52-Week High | $26.53 | $278.43 |
52-Week Low | $17.87 | $186.00 |
Typical Hold Time | 62 Days | 129 Days |
Enterprise Value | $12.03B | $646.37B |
Dividend Yield | — | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GameStop (GME) trades at $26.37, up 7.28% in 24 hours, with a bullish technical signal and strong insider buying by CEO Ryan Cohen. The company reported net income of $131.3 million in 2025, a significant turnaround from prior losses, though revenue declined to $3.82 billion. Valuation ratios include a P/E of 16.63 and P/S of 4.22, while analyst consensus remains mixed with 16.67% buy ratings.
The outlook hinges on sustained profitability and strategic shifts, but risks include revenue volatility and competitive pressures. Insider confidence provides near-term support, yet the stock faces headwinds from cautious Wall Street sentiment and execution challenges in a declining physical retail environment.
Johnson & Johnson (JNJ) trades at $259.62, up 0.45% with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 21.48% net margin and 25.74% ROE, though valuation ratios appear elevated with P/E at 29.75. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with 52.5% buy ratings.
JNJ offers stable dividend income and pharmaceutical innovation upside, but faces patent cliff risks and increasing debt-to-asset ratio (24.06% in 2025). Analyst consensus target of $286.53 suggests 10% upside potential, though technical resistance at $260 may limit near-term gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GameStop Corp.
Global Market Group Ltd. operates an Internet website that connects Chinese manufacturers with international buyers. The Company's customers can post company profiles and product information in standardized formats; post product listings; and trade leads.
Read more on GME →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
